oxidopamine has been researched along with Dyskinesia, Drug-Induced in 348 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 7.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| " Intact male GPR88 KO mice showed diminished tacrine-induced PD-like tremor and spontaneous hyperlocomotion." | 3.96 | Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia. ( Mannoury-la-Cour, C; Mantas, I; Millan, MJ; Svenningsson, P; Yang, Y; Zhang, X, 2020) |
| "Levodopa-induced dyskinesia (LID) is a persistent behavioral sensitization that develops after repeated levodopa (l-DOPA) exposure in Parkinson disease patients." | 3.83 | Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia. ( Eskow Jaunarajs, KL; Figge, DA; Standaert, DG, 2016) |
| " The aims of this study were therefore (1) to investigate the anti-dyskinetic effects of piribedil on L-DOPA-induced contralateral turning behaviour, locomotive dyskinesias (LD), axial dystonia (AD), orolingual dyskinesia (OD) and forelimb dyskinesia (FD) and (2) to compare these effects to the α(2) adrenoceptor antagonist, idazoxan, or the α(2) adrenoceptor agonist, clonidine." | 3.79 | The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms. ( Gerlach, M; Halley, P; Riederer, P; van den Buuse, M, 2013) |
| "As an index of terminal serotonin innervation density, we measured radioligand binding to the plasma membrane serotonin transporter (SERT) in levodopa-treated dyskinetic and nondyskinetic subjects, using brain tissue from both rat and monkey models of Parkinson disease as well as parkinsonian patients." | 3.76 | Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. ( Bezard, E; Cenci, MA; Descarries, L; Dovero, S; Lees, AJ; O'Sullivan, SS; Parent, M; Rylander, D, 2010) |
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 3.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| "One major goal of current research in Parkinson's disease (PD) is the discovery of novel agents to improve symptomatic management." | 2.42 | Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. ( Linazasoro, G, 2004) |
| " Involuntary movements were assessed by two blinded raters prior and every 30 min after drug dosing using the Clinical Dyskinesia Rating Scale (CDRS)." | 1.91 | Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration. ( Cenci, MA; Espa, E; Grigoriou, S; Jakobsson, A; Odin, P; Timpka, J; von Grothusen, G, 2023) |
| "Cabergoline co-treatment with L-dopa reduced LID, striatal preprodynorphin mRNA expression, and hypertrophy of the entopeduncular nucleus, indicating that cabergoline has an anti-LID effect independent of the L-dopa-sparing effect." | 1.72 | Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease. ( Kimura, T; Kinoshita, I; Kon, T; Miki, Y; Mori, F; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M; Wakabayashi, K, 2022) |
| "In advanced stages of Parkinson's disease (PD), dyskinesia and motor fluctuations become seriously debilitating and therapeutic options become scarce." | 1.72 | D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice. ( Murer, MG; Paz, RM; Rela, L; Stahl, AM; Tubert, C, 2022) |
| " We then assessed the efficacy of bitopertin on dyskinesia in the context of acute challenge and chronic administration studies." | 1.72 | Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat. ( Bédard, D; Belliveau, S; Bourgeois-Cayer, É; Frouni, I; Hadj-Youssef, S; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Ohlund, L; Sleno, L, 2022) |
| "In Parkinson's disease (PD), long-term administration of L-dopa often leads to L-dopa-induced dyskinesia (LID), a debilitating motor complication." | 1.62 | The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease. ( Liu, Z; Song, L; Yan, A; Yang, S; Zhao, J, 2021) |
| "However, unwanted involuntary movements known as L-DOPA-induced dyskinesias (LIDs) develop with prolonged use of this dopamine precursor." | 1.62 | Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease. ( Caulfield, ME; Stancati, JA; Steece-Collier, K, 2021) |
| "We found that the 10 mg/kg l-dopa dosing regimen induced LID in all animals (n = 5) and induced significant angiogenesis in the striatum and substantia nigra." | 1.62 | The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia. ( Anderson, C; Booth, S; Jackson, MF; Kirouac, G; Ko, JH; Lu, L; Ramadan, A; Zhang, D, 2021) |
| " However, a U-shaped dose-response curve obtained with certain parameters may limit the therapeutic potential of this strategy and require further investigation." | 1.62 | Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat. ( Bédard, D; Frouni, I; Hamadjida, A; Huot, P; Kwan, C, 2021) |
| "The effect of marijuana on Parkinson's disease is controversial and Medical marijuana may benefit for motor and non-motor symptoms of patients with Parkinson's disease." | 1.62 | Marijuana improved motor impairments and changes in synaptic plasticity-related molecules in the striatum in 6-OHDA-treated rats. ( Haghparast, E; Komeili, G; Sheibani, V, 2021) |
| "Parkinson's disease is a progressive neurodegenerative disease characterized by striatal dopaminergic loss." | 1.56 | D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects. ( Brevard, J; Fonseca, KR; Gray, DL; Kozak, R; Popiolek, M; Trapa, P; Young, D, 2020) |
| "Dopamine replacement therapy using L-3,4-dihydroxyphenylalanine (L-DOPA) is a gold standard treatment in patients with Parkinson's disease (PD); however, chronic administration of L-DOPA causes excessive involuntary movements called L-DOPA-induced dyskinesia." | 1.56 | Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats. ( Arakawa, K; Maehara, S; Yuge, N, 2020) |
| " Chronic administration of L-DOPA plus ZNS in PD model mice was shown to increase the duration and severity of LID compared with PD model mice that were treated with L-DOPA alone." | 1.51 | The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice. ( Nambu, A; Sano, H, 2019) |
| " However, its long-term use is limited due to motor complications such as wearing-off and dyskinesia." | 1.48 | Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements. ( Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H, 2018) |
| " In this study, we found that CaMKIIa was found to form complexes with GluN2B after chronic administration of L-dopa in adult rat striatal neurons." | 1.48 | Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats. ( Chen, SY; Shao, B; Wang, XS; Xie, CL; Zhang, XR; Zhang, ZR, 2018) |
| "Safinamide (Xadago) is a novel dual-mechanism drug that has been approved in the European Union and United States as add-on treatment to levodopa in Parkinson's disease therapy." | 1.48 | Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia. ( Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S, 2018) |
| "L-3,4-dihydroxyphenylalanine (L-dopa) remains the most effective therapy for Parkinson's disease (PD), but its long-term administration is associated with the development of debilitating motor complications known as L-dopa-induced dyskinesia (LID)." | 1.43 | Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats. ( Cheng, J; Fan, Q; Gan, J; Hu, R; Li, L; Liu, Z; Song, L; Wu, N; Zhang, Z; Zhou, M, 2016) |
| " We used the 6-hydroxydopamine (6-OHDA) rat model of PD treated with a three-week dosing regimen of L-DOPA plus the dopa decarboxylase inhibitor benserazide (4 mg/kg and 7." | 1.43 | Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat. ( Black, MA; Dearden, PK; Duncan, EJ; Gemmell, NJ; Parr-Brownlie, LC; Reynolds, JN; Smith, LM, 2016) |
| "The dyskinesia of Parkinson's Disease is most likely due to excess levels of dopamine in the striatum." | 1.43 | Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease. ( Boon, WC; Chua, HK; Horne, M; Stanic, D; Tomas, D; White, K, 2016) |
| "L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective treatment for Parkinson's disease, but chronic administration is complicated by the development of dyskinesia." | 1.42 | L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. ( Brotchie, JM; Espinosa, MC; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Reyes, MG, 2015) |
| " Levodopa-induced dyskinesias (LID) can be modeled in rats with unilateral 6-OHDA lesions via chronic administration of levodopa, which causes increasingly severe axial, limb, and orofacial abnormal involuntary movements (AIMs) over time." | 1.42 | Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. ( Carta, AR; Cassano, T; Giuffrida, A; Macheda, T; Martinez, AA; Morgese, MG; Paquette, MA; Pisanu, A; Seillier, A, 2015) |
| "The increase in dyskinesias when parkinsonism becomes bilateral was mostly due to an increase in orolingual dyskinesias associated to a increase in PDyn mRNA expression." | 1.42 | From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms. ( Bonastre, M; Cortés, R; Marin, C; Mengod, G; Rodríguez-Oroz, MC, 2015) |
| " Chronic use of SOMCL-171 reduced LID without compromising the antiparkinsonian efficacy." | 1.40 | (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease. ( Fang, X; Guo, L; Jia, J; Liu, Z; Lu, W; Yang, Z; Ye, N; Zhang, A; Zhao, B; Zhao, J; Zhao, R; Zhen, X; Zheng, L, 2014) |
| " It is established that the antidyskinetic effect of the injectable dosage form of a new antiparkinsonian drug hemantane (5 mg/kg) after a single intravenous administration is weaker than that of the most effective in clinical practice antidyskinetic drug amantadine (20 mg/kg)." | 1.40 | [Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome]. ( Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA, 2014) |
| " Unfortunately, chronic administration of this dopamine precursor causes L-DOPA-induced dyskinesia (LID), which is a debilitating complication whose pathogenesis remains unclear." | 1.40 | Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia. ( Liu, J; Wang, HS; Wang, T; Wang, Y; Zhang, QJ, 2014) |
| "The long-term use of levodopa (L-DOPA) in Parkinson's disease (PD) results in the development of abnormal involuntary movements called L-DOPA-induced dyskinesias." | 1.40 | Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease. ( González-Aparicio, R; Moratalla, R, 2014) |
| " The long-term use of LD is limited by the development of L-DOPA-induced dyskinesias and dystonia." | 1.39 | The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia. ( Aley-Medina, P; Anaya-Martínez, V; Avila-Costa, MR; Espinosa-Villanueva, J; García-Ruiz, R; Gutiérrez-Valdez, AL; Montiel-Flores, E; Reynoso-Erazo, L; Sánchez-Betancourt, J; Torres-Esquivel, C; Tron-Alvarez, R, 2013) |
| " To test this hypothesis in a rodent model, the A2A receptor antagonists SCH 412348 (3 mg/kg), vipadenant (10 mg/kg), caffeine (30 mg/kg), or istradefylline (3 mg/kg) were chronically (19-22 days) administered to Sprague Dawley rats, and dyskinetic behaviors were scored across this chronic dosing paradigm." | 1.39 | A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. ( Bleickardt, C; Hodgson, R; Jones, N; Mullins, D; Parker, E, 2013) |
| "L-DOPA alleviates the motor symptoms of Parkinson's disease, but its long-term use is associated with undesirable dyskinesia." | 1.39 | Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice. ( Aguiar, AS; Córdova, FM; Cunha, RA; Glaser, V; Hoeller, AA; Latini, A; Leal, RB; Moreira, EL; Oliveira, PA; Prediger, RD; Walz, R, 2013) |
| " MRZ-8676 (6,6-dimethyl-2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one) is a novel proprietary, selective, orally bioavailable mGluR5 NAM." | 1.37 | Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia. ( Danysz, W; Dekundy, A; Gravius, A; Hechenberger, M; Mela, F; Nagel, J; Parsons, CG; Pietraszek, M; Tober, C; van der Elst, M, 2011) |
| " Although, using these parameters, re-exposure in the presence of saline did not induce context-dependent AIMs, a strong context-specific component of the sensitised response to l-DOPA was seen; chronic administration of drug produced a significantly stronger behavioural response in animals paired with a particular environment for drug administration than controls." | 1.37 | Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat. ( Daly, CS; Dunnett, SB; Lane, EL; Smith, GA, 2011) |
| "L-dopa therapy for Parkinson's disease leads to dyskinesias or abnormal involuntary movement (AIMs) for which there are few treatment options." | 1.37 | Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats. ( Campos, C; Huang, LZ; Ivy Carroll, F; Ly, J; Quik, M, 2011) |
| " Chronic use of (-)-15 reduced L-DOPA-induced dyskinesia (LID) without attenuating the antiparkinsonian effect." | 1.37 | Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile. ( Gao, B; Guo, L; Liu, Z; Ye, N; Zhang, A; Zhang, H; Zhen, X; Zheng, L; Zhou, S, 2011) |
| " The chronic administration of these drugs together with amantadine (20 mg/kg) accelerates the onset of latency and increases the magnitude of dyskinesia." | 1.37 | [Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome]. ( Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA, 2011) |
| "Treatment with sarizotan (1 or 5 mg/kg ip) dose-dependently inhibited the L: -DOPA-induced contraversive turning and AIMs." | 1.37 | Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. ( Bartoszyk, GD; Dean, O; Gerlach, M; Riederer, P; van den Buuse, M, 2011) |
| "Chronic levodopa treatment for Parkinson's disease often results in the development of abnormal involuntary movement, known as L-dopa-induced dyskinesia (LIDs)." | 1.36 | Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment. ( Belujon, P; Grace, AA; Lodge, DJ, 2010) |
| " However, the symptomatic relief provided by long-term administration may be compromised by L: -DOPA-induced dyskinesia (LID) that presents as adverse fluctuations in motor responsiveness and progressive loss of motor control." | 1.36 | The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model. ( Gil, S; Koh, H; Lee, J; Park, C, 2010) |
| " However, both acute and chronic administration of S33084 enhanced L-DOPA-induced contralateral turning, suggesting potential antiparkinsonian properties." | 1.36 | The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats. ( Brocco, M; Mela, F; Millan, MJ; Morari, M, 2010) |
| "In Parkinson's disease (PD), the long term use of L-DOPA results in major adverse effects including dyskinesia or abnormal involuntary movements." | 1.36 | The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. ( Buck, K; Ferger, B, 2010) |
| "L-DOPA-induced dyskinesia in Parkinson's disease is associated with large increases in brain dopamine (DA) levels following drug dosing, but the precise significance of this phenomenon is not understood." | 1.36 | L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. ( Andersson, DR; Cenci, MA; Lagerkvist, S; Lindgren, HS; Nissbrandt, H, 2010) |
| " Chronic administration of fenobam to previously drug-naïve animals (de novo treatment) attenuated the development of peak-dose dyskinesia without compromising the anti-parkinsonian effect of L-DOPA." | 1.36 | A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. ( Baishen, R; Bezard, E; Cenci, MA; Danysz, W; Dekundy, A; Iderberg, H; Li, H; Li, Q; Rylander, D; Zhang, J, 2010) |
| " We now show that they are associated with the chronic administration of L-DOPA prior to the transplantation surgery." | 1.35 | Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. ( Brundin, P; Cenci, MA; Lane, EL; Vercammen, L, 2009) |
| "Isradipine-treated animals displayed a dose-dependent reduction in L-DOPA-induced rotational behavior and abnormal involuntary movements." | 1.35 | Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. ( Aubert, I; Berthet, A; Bezard, E; Bloch, B; Cenci, MA; Doudnikoff, E; Hengerer, B; Ittrich, C; Rylander, D; Schuster, S; Surmeier, DJ, 2009) |
| "Patients with Parkinson's disease that receive transplants of foetal ventral mesencephalic tissue, the graft cell preparation is likely to contain, in addition to dopamine neurons, serotonin neurons that will vary in number depending on the landmarks used for dissection." | 1.35 | Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. ( Björklund, A; Carlsson, T; Carta, M; Kirik, D; Mattsson, B; Muñoz, A; Winkler, C, 2009) |
| "Current treatments for Parkinson's disease rely on a dopamine replacement strategy and are reasonably effective, particularly in the early stages of the disease." | 1.35 | Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model. ( Dunnett, SB; Lane, EL; Monville, C; Pekarik, V; Torres, EM, 2009) |
| " While it has been suggested that the daily dose of l-DOPA can play a critical role, the mechanisms linking l-DOPA dosage to the occurrence of motor complications have not yet been explored." | 1.35 | l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. ( Angela Cenci, M; Bagetta, V; Barone, I; Bernardi, G; Calabresi, P; Ghiglieri, V; Lindgren, HS; Paillé, V; Picconi, B, 2008) |
| "Pretreatment with zaprinast reduced the severity of levodopa-induced dyskinesias, and partly prevented the decrease in cyclic nucleotides compared with pretreatment with saline-levodopa." | 1.35 | Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. ( Bernardi, G; D'Angelo, V; Esposito, Z; Giorgi, M; Martorana, A; Nuccetelli, V; Sancesario, G; Sorge, R; Stefani, A, 2008) |
| "Chronic L-DOPA pharmacotherapy in Parkinson's disease is often accompanied by the development of abnormal and excessive movements known as L-DOPA-induced dyskinesia." | 1.35 | Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. ( Del-Bel, EA; Echeverry, MB; Padovan-Neto, FE; Tumas, V, 2009) |
| "In patients with Parkinson's disease, the therapeutic efficacy of L-DOPA medication is gradually lost over time, and abnormal involuntary movements, dyskinesias, gradually emerge as a prominent side-effect in response to previously beneficial doses of the drug." | 1.34 | Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. ( Björklund, A; Carlsson, T; Carta, M; Kirik, D, 2007) |
| " Although levodopa improves PD symptoms in the initial stages of the disease, its long-term use is limited by the development of side effects, including abnormal involuntary movements (dyskinesias) and psychiatric complications." | 1.34 | Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. ( Cassano, T; Cuomo, V; Giuffrida, A; Morgese, MG, 2007) |
| " Catechol-O-methyltransferase (COMT) inhibitors increase the half-life and bioavailability of levodopa, providing more continuous dopamine receptor stimulation." | 1.33 | Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. ( Aguilar, E; Bonastre, M; Marin, C; Obeso, JA; Tolosa, E, 2005) |
| "Moreover, Arc is preferentially induced, along with FosB, nur77, and homer-1a, in striatonigral neurons, which express mRNA encoding the precursor of dynorphin." | 1.33 | Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. ( Benabid, AL; Berger, F; Buggia, V; Gilbert, F; Lévesque, D; Sgambato-Faure, V, 2005) |
| "Current treatments for Parkinson's disease (PD) rely on a dopamine replacement strategy and are reasonably effective, particularly in the early stages of the disease." | 1.33 | Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. ( Dunnett, SB; Monville, C; Torres, EM, 2005) |
| " Individual differences in the central bioavailability of L-DOPA may provide a clue to the varying susceptibility to dyskinesia in Parkinson's disease." | 1.33 | Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. ( Carta, M; Cenci, MA; Fadda, F; Lindgren, HS; Lundblad, M; Stancampiano, R, 2006) |
| "Aripiprazole has been extensively studied pre-clinically, both in vitro and in vivo, and these results have been correlated with clinical findings." | 1.33 | Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. ( Clarke, K; Davies, CH; Forbes, IT; Gribble, A; Hill, M; Jones, DN; Newson, M; Reavill, C; Rourke, C; Scott, C; Westaway, J; Wood, MD, 2006) |
| "Ritanserin pretreatment blunted systemic SKF 82958-induced hyperlocomotion and returned intrastriatal D1-mediated hyperactivity to sham lesion levels." | 1.32 | Intrastriatal serotonin 5-HT2 receptors mediate dopamine D1-induced hyperlocomotion in 6-hydroxydopamine-lesioned rats. ( Bishop, C; Kamdar, DP; Walker, PD, 2003) |
| "The majority of Parkinson's disease patients undergoing levodopa therapy develop disabling motor complications (dyskinesias) within 10 years of treatment." | 1.32 | Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. ( Asbrock, N; Ferrer, B; Giuffrida, A; Kathuria, S; Piomelli, D, 2003) |
| " This phenomenon, referred to as sensitization, is believed to be related to the motor response complications (dyskinesias, on-off states) that occur during chronic administration of levodopa in Parkinson's disease patients." | 1.32 | Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. ( Delfino, MA; Ferrario, JE; Gershanik, OS; Murer, MG; Stefano, AV; Taravini, IR, 2004) |
| " These results are consistent with previous work highlighting the importance of aberrant amine production in neurological disease and demonstrate that treatments that reduce endogenous melatonin bioavailability can ameliorate experimental PD." | 1.30 | A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. ( Armstrong, SM; Willis, GL, 1999) |
| "Chronic L-DOPA treatment of Parkinson's disease frequently leads to the development of motoric overstimulation and hyperkinetic movements." | 1.28 | Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue. ( Carey, RJ, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.57) | 18.7374 |
| 1990's | 13 (3.74) | 18.2507 |
| 2000's | 83 (23.85) | 29.6817 |
| 2010's | 188 (54.02) | 24.3611 |
| 2020's | 62 (17.82) | 2.80 |
| Authors | Studies |
|---|---|
| Iyer, V | 1 |
| Venkiteswaran, K | 2 |
| Savaliya, S | 1 |
| Lieu, CA | 3 |
| Handly, E | 1 |
| Gilmour, TP | 1 |
| Kunselman, AR | 2 |
| Subramanian, T | 3 |
| Tohge, R | 1 |
| Kaneko, S | 1 |
| Morise, S | 1 |
| Oki, M | 1 |
| Takenouchi, N | 1 |
| Murakami, A | 1 |
| Nakamura, M | 1 |
| Kusaka, H | 1 |
| Yakushiji, Y | 1 |
| Bariotto-Dos-Santos, K | 3 |
| Ribeiro, DL | 1 |
| Guimarães, RP | 1 |
| Padovan-Neto, FE | 7 |
| Caulfield, ME | 1 |
| Stancati, JA | 4 |
| Steece-Collier, K | 5 |
| Kwan, C | 3 |
| Lévesque, C | 1 |
| Bédard, D | 3 |
| Frouni, I | 3 |
| Yesuf, JM | 1 |
| Hamadjida, A | 3 |
| Lévesque, D | 2 |
| Clarke, PB | 1 |
| Huot, P | 4 |
| Nishijima, H | 3 |
| Mori, F | 1 |
| Kimura, T | 1 |
| Miki, Y | 1 |
| Kinoshita, I | 2 |
| Nakamura, T | 2 |
| Kon, T | 2 |
| Suzuki, C | 2 |
| Wakabayashi, K | 1 |
| Tomiyama, M | 3 |
| Calderón, VM | 1 |
| Luna-Leal, A | 1 |
| Gómez-Paz, A | 1 |
| Ramírez-López, F | 1 |
| Arias-García, M | 1 |
| Lara-González, E | 1 |
| Galarraga, E | 1 |
| Bargas, J | 1 |
| Elabi, OF | 1 |
| Pass, R | 1 |
| Sormonta, I | 1 |
| Nolbrant, S | 1 |
| Drummond, N | 1 |
| Kirkeby, A | 1 |
| Kunath, T | 1 |
| Parmar, M | 2 |
| Lane, EL | 10 |
| Cohen, SR | 1 |
| Terry, ML | 1 |
| Coyle, M | 1 |
| Wheelis, E | 1 |
| Centner, A | 3 |
| Smith, S | 1 |
| Glinski, J | 3 |
| Lipari, N | 3 |
| Budrow, C | 1 |
| Manfredsson, FP | 6 |
| Bishop, C | 19 |
| Paz, RM | 3 |
| Stahl, AM | 1 |
| Rela, L | 1 |
| Murer, MG | 7 |
| Tubert, C | 1 |
| Tseng, KY | 2 |
| Kuo, TT | 2 |
| Wang, V | 2 |
| Huang, EY | 2 |
| Ma, KH | 2 |
| Olson, L | 2 |
| Hoffer, BJ | 2 |
| Chen, YH | 2 |
| Kang, W | 1 |
| Belliveau, S | 1 |
| Hadj-Youssef, S | 1 |
| Bourgeois-Cayer, É | 1 |
| Ohlund, L | 1 |
| Sleno, L | 1 |
| Calabrese, V | 1 |
| Picconi, B | 10 |
| Heck, N | 1 |
| Campanelli, F | 1 |
| Natale, G | 1 |
| Marino, G | 1 |
| Sciaccaluga, M | 1 |
| Ghiglieri, V | 7 |
| Tozzi, A | 4 |
| Anceaume, E | 1 |
| Cuoc, E | 1 |
| Caboche, J | 2 |
| Conquet, F | 1 |
| Calabresi, P | 10 |
| Charvin, D | 1 |
| Thomsen, M | 1 |
| Stoica, A | 1 |
| Christensen, KV | 1 |
| Fryland, T | 1 |
| Mikkelsen, JD | 1 |
| Hansen, JB | 1 |
| Cesaroni, V | 2 |
| Blandini, F | 3 |
| Cerri, S | 2 |
| Cohen, S | 2 |
| Espa, E | 3 |
| Song, L | 4 |
| Skovgård, K | 1 |
| Fanni, S | 3 |
| Cenci, MA | 29 |
| Yuan, Y | 1 |
| Zhang, X | 2 |
| Wu, Y | 1 |
| Lian, P | 1 |
| Cao, X | 4 |
| Xu, Y | 2 |
| Corsi, S | 2 |
| Scheggi, S | 2 |
| Pardu, A | 1 |
| Braccagni, G | 1 |
| Caruso, D | 1 |
| Cioffi, L | 1 |
| Diviccaro, S | 1 |
| Gentile, M | 1 |
| Stancampiano, R | 6 |
| Gambarana, C | 2 |
| Melcangi, RC | 1 |
| Frau, R | 1 |
| Carta, M | 17 |
| Greig, NH | 2 |
| Jung, J | 1 |
| Choi, HI | 1 |
| Liu, K | 1 |
| Song, M | 1 |
| Gao, S | 1 |
| Yao, L | 2 |
| Zhang, L | 2 |
| Feng, J | 1 |
| Wang, L | 1 |
| Gao, R | 1 |
| Wang, Y | 6 |
| Murakami, Y | 1 |
| Furukawa, T | 1 |
| Avila-Luna, A | 2 |
| Gálvez-Rosas, A | 2 |
| Aguirre-Pérez, A | 1 |
| Hidalgo-Bravo, A | 1 |
| Alfaro-Rodriguez, A | 1 |
| Ríos, C | 2 |
| Arias-Montaño, JA | 2 |
| Bueno-Nava, A | 2 |
| Kambey, PA | 1 |
| Liu, WY | 1 |
| Wu, J | 1 |
| Tang, C | 1 |
| Buberwa, W | 1 |
| Saro, A | 1 |
| Nyalali, AMK | 1 |
| Gao, D | 1 |
| Grigoriou, S | 1 |
| Odin, P | 1 |
| Timpka, J | 1 |
| von Grothusen, G | 1 |
| Jakobsson, A | 1 |
| Pelosi, A | 1 |
| Nakamura, Y | 1 |
| Girault, JA | 4 |
| Hervé, D | 4 |
| Nascimento, GC | 2 |
| Jacob, G | 1 |
| Milan, BA | 1 |
| Leal-Luiz, G | 1 |
| Malzone, BL | 1 |
| Vivanco-Estela, AN | 1 |
| Escobar-Espinal, D | 1 |
| Dias, FJ | 1 |
| Del-Bel, E | 6 |
| Abe, Y | 1 |
| Yagishita, S | 1 |
| Sano, H | 2 |
| Sugiura, Y | 1 |
| Dantsuji, M | 1 |
| Suzuki, T | 1 |
| Mochizuki, A | 1 |
| Yoshimaru, D | 1 |
| Hata, J | 1 |
| Matsumoto, M | 1 |
| Taira, S | 1 |
| Takeuchi, H | 1 |
| Okano, H | 1 |
| Ohno, N | 1 |
| Suematsu, M | 1 |
| Inoue, T | 1 |
| Nambu, A | 2 |
| Watanabe, M | 1 |
| Tanaka, KF | 1 |
| Flores, AJ | 2 |
| Bartlett, MJ | 3 |
| Seaton, BT | 1 |
| Samtani, G | 1 |
| Sexauer, MR | 1 |
| Weintraub, NC | 1 |
| Siegenthaler, JR | 1 |
| Lu, D | 1 |
| Heien, ML | 2 |
| Porreca, F | 2 |
| Sherman, SJ | 3 |
| Falk, T | 3 |
| Lelos, MJ | 1 |
| Murphy, EM | 1 |
| Lindgren, HS | 5 |
| Dunnett, SB | 8 |
| Aristieta, A | 3 |
| Ruiz-Ortega, JA | 4 |
| Morera-Herreras, T | 3 |
| Miguelez, C | 5 |
| Ugedo, L | 5 |
| Mantas, I | 1 |
| Yang, Y | 1 |
| Mannoury-la-Cour, C | 1 |
| Millan, MJ | 3 |
| Svenningsson, P | 2 |
| Vaz, RL | 1 |
| Chapela, D | 1 |
| Coelho, JE | 1 |
| Lopes, LV | 1 |
| Ferreira, JJ | 1 |
| Afonso, ND | 1 |
| Sousa, S | 1 |
| Outeiro, TF | 1 |
| Young, D | 1 |
| Popiolek, M | 1 |
| Trapa, P | 1 |
| Fonseca, KR | 1 |
| Brevard, J | 1 |
| Gray, DL | 1 |
| Kozak, R | 1 |
| Castello, J | 1 |
| Cortés, M | 1 |
| Malave, L | 1 |
| Kottmann, A | 1 |
| Sibley, DR | 1 |
| Friedman, E | 1 |
| Rebholz, H | 1 |
| Zheng, C | 1 |
| Chen, G | 1 |
| Tan, Y | 1 |
| Zeng, W | 1 |
| Wang, J | 1 |
| Cheng, C | 2 |
| Yang, X | 4 |
| Nie, S | 1 |
| Zhang, Z | 3 |
| Arakawa, K | 1 |
| Yuge, N | 1 |
| Maehara, S | 1 |
| Chen, X | 1 |
| Wu, H | 1 |
| Le, W | 1 |
| Koski, SK | 2 |
| Leino, S | 2 |
| Panula, P | 1 |
| Rannanpää, S | 2 |
| Salminen, O | 2 |
| Sellnow, RC | 1 |
| Altwal, F | 1 |
| Sandoval, IM | 3 |
| Kordower, JH | 1 |
| Collier, TJ | 4 |
| Sortwell, CE | 4 |
| West, AR | 1 |
| Wang, R | 1 |
| Shao, M | 1 |
| Leija-Salazar, M | 1 |
| Bermúdez de León, M | 1 |
| González-Horta, A | 1 |
| González-Hernández, B | 1 |
| Rossi, F | 2 |
| Tronci, E | 8 |
| Ludovica, C | 1 |
| Vargiu, R | 1 |
| Muñoz, A | 7 |
| Björklund, A | 10 |
| Marin, C | 9 |
| Bonastre, M | 6 |
| Fuentes, M | 2 |
| Mullol, J | 2 |
| Brugnoli, A | 3 |
| Pisanò, CA | 3 |
| Morari, M | 8 |
| Lopez-Lopez, A | 1 |
| Labandeira, CM | 1 |
| Labandeira-Garcia, JL | 4 |
| Booth, S | 1 |
| Ramadan, A | 1 |
| Zhang, D | 1 |
| Lu, L | 1 |
| Kirouac, G | 1 |
| Jackson, MF | 1 |
| Anderson, C | 1 |
| Ko, JH | 1 |
| Mercado, NM | 2 |
| Mueller, RL | 1 |
| Boezwinkle, SA | 1 |
| Duffy, MF | 1 |
| Fischer, DL | 1 |
| Güttler, C | 1 |
| Altschüler, J | 1 |
| Tanev, K | 1 |
| Böckmann, S | 1 |
| Haumesser, JK | 1 |
| Nikulin, VV | 1 |
| Kühn, AA | 1 |
| van Riesen, C | 1 |
| Feyder, M | 2 |
| Plewnia, C | 1 |
| Lieberman, OJ | 1 |
| Spigolon, G | 2 |
| Piccin, A | 1 |
| Urbina, L | 1 |
| Dehay, B | 2 |
| Li, Q | 8 |
| Nilsson, P | 1 |
| Altun, M | 1 |
| Santini, E | 4 |
| Sulzer, D | 1 |
| Bezard, E | 14 |
| Borgkvist, A | 2 |
| Fisone, G | 6 |
| Rivas-Santisteban, R | 1 |
| Lillo, J | 1 |
| Rodríguez-Pérez, AI | 1 |
| Navarro, G | 2 |
| Franco, R | 2 |
| Ye, T | 1 |
| Cowen, SL | 1 |
| Ferrari, DP | 1 |
| Bortolanza, M | 6 |
| Del Bel, EA | 1 |
| Beck, G | 1 |
| Zhang, J | 2 |
| Fong, K | 1 |
| Mochizuki, H | 1 |
| Mouradian, MM | 1 |
| Papa, SM | 1 |
| do Nascimento, GC | 1 |
| Raisman-Vozari, R | 5 |
| Komeili, G | 1 |
| Haghparast, E | 1 |
| Sheibani, V | 1 |
| Liu, Z | 6 |
| Yan, A | 1 |
| Zhao, J | 2 |
| Yang, S | 1 |
| Andreoli, L | 1 |
| Abbaszadeh, M | 1 |
| Pinna, A | 5 |
| Costa, G | 1 |
| Serra, M | 1 |
| Contu, L | 1 |
| Morelli, M | 5 |
| Solís, O | 5 |
| García-Montes, JR | 1 |
| Garcia-Sanz, P | 2 |
| Herranz, AS | 2 |
| Asensio, MJ | 2 |
| Kang, G | 1 |
| Hiroi, N | 1 |
| Moratalla, R | 10 |
| Alam, M | 2 |
| Rumpel, R | 1 |
| Jin, X | 2 |
| von Wrangel, C | 1 |
| Tschirner, SK | 1 |
| Krauss, JK | 2 |
| Grothe, C | 1 |
| Ratzka, A | 1 |
| Schwabe, K | 2 |
| Zhou, X | 1 |
| Doorduin, J | 1 |
| Elsinga, PH | 1 |
| Dierckx, RAJO | 1 |
| de Vries, EFJ | 1 |
| Casteels, C | 1 |
| Chotibut, T | 1 |
| Meadows, S | 1 |
| Kasanga, EA | 1 |
| McInnis, T | 1 |
| Cantu, MA | 1 |
| Salvatore, MF | 1 |
| Napolitano, F | 5 |
| Fidalgo, C | 4 |
| Usiello, A | 7 |
| Stanic, J | 2 |
| Mellone, M | 3 |
| Racca, C | 1 |
| Zianni, E | 3 |
| Minocci, D | 1 |
| Thiolat, ML | 1 |
| Longhi, A | 1 |
| De Rosa, A | 1 |
| Di Luca, M | 3 |
| Gardoni, F | 6 |
| Johnston, TH | 3 |
| Versi, E | 1 |
| Howson, PA | 1 |
| Ravenscroft, P | 5 |
| Fox, SH | 3 |
| Hill, MP | 1 |
| Reidenberg, BE | 1 |
| Corey, R | 1 |
| Brotchie, JM | 8 |
| Arcuri, L | 2 |
| Novello, S | 2 |
| Frassineti, M | 1 |
| Mercatelli, D | 2 |
| Morella, I | 3 |
| Fasano, S | 3 |
| Journigan, BV | 1 |
| Meyer, ME | 1 |
| Polgar, WE | 1 |
| Brambilla, R | 3 |
| Zaveri, NT | 1 |
| Francardo, V | 4 |
| Zhu, Z | 1 |
| Ding, X | 1 |
| Wang, X | 2 |
| Cui, G | 2 |
| Hua, F | 2 |
| Xiang, J | 1 |
| Caro Aponte, PA | 1 |
| Otálora, CA | 1 |
| Guzmán, JC | 1 |
| Turner, LF | 1 |
| Alcázar, JP | 1 |
| Mayorga, EL | 1 |
| Tsunekawa, H | 1 |
| Takahata, K | 1 |
| Okano, M | 1 |
| Ishikawa, T | 1 |
| Satoyoshi, H | 1 |
| Nishimura, T | 1 |
| Hoshino, N | 1 |
| Muraoka, S | 1 |
| Zhang, GJ | 1 |
| Sun, YN | 1 |
| Wang, HS | 3 |
| Du, CX | 1 |
| Liu, J | 3 |
| Leite-Panissi, CRA | 1 |
| Del-Bel, EA | 2 |
| Baufreton, J | 1 |
| Milekovic, T | 1 |
| McGuire, S | 1 |
| Moraud, EM | 1 |
| Porras, G | 2 |
| Sun, S | 1 |
| Ko, WKD | 1 |
| Chazalon, M | 1 |
| Morin, S | 1 |
| Normand, E | 1 |
| Farjot, G | 1 |
| Milet, A | 1 |
| Pype, J | 1 |
| Pioli, E | 1 |
| Courtine, G | 1 |
| Bessière, B | 1 |
| Hänninen, R | 1 |
| Tapanainen, T | 1 |
| Ryu, YK | 2 |
| Park, HY | 2 |
| Go, J | 2 |
| Kim, YH | 2 |
| Hwang, JH | 2 |
| Choi, DH | 2 |
| Noh, JR | 1 |
| Rhee, M | 2 |
| Han, PL | 1 |
| Lee, CH | 2 |
| Kim, KS | 2 |
| Dos-Santos-Pereira, M | 3 |
| Tumas, V | 2 |
| Del Bel, E | 3 |
| Kim, YK | 1 |
| Lee, AR | 1 |
| Park, H | 1 |
| Yoo, J | 1 |
| Ahn, S | 1 |
| Jeon, SH | 1 |
| Kim, J | 2 |
| Park, HJ | 3 |
| Wang, XS | 1 |
| Zhang, ZR | 1 |
| Zhang, XR | 1 |
| Chen, SY | 1 |
| Shao, B | 1 |
| Xie, CL | 2 |
| Root, BK | 1 |
| Parent, KL | 1 |
| Polt, R | 1 |
| Kulisevsky, J | 2 |
| Caccia, C | 1 |
| Melloni, E | 1 |
| Padoani, G | 1 |
| Sosti, V | 1 |
| Vailati, S | 1 |
| Keywood, C | 1 |
| Pagliaroli, L | 1 |
| Widomska, J | 1 |
| Nespoli, E | 1 |
| Hildebrandt, T | 1 |
| Barta, C | 1 |
| Glennon, J | 1 |
| Hengerer, B | 2 |
| Poelmans, G | 1 |
| Meadows, SM | 1 |
| Conti, MM | 3 |
| Gross, L | 1 |
| Chambers, NE | 1 |
| Avnor, Y | 1 |
| Ostock, CY | 7 |
| Lanza, K | 1 |
| Rentsch, P | 1 |
| Stayte, S | 1 |
| Morris, GP | 1 |
| Vissel, B | 1 |
| Montes, S | 1 |
| Keifman, E | 1 |
| Ruiz-DeDiego, I | 2 |
| Pafundo, DE | 1 |
| Collier, NJ | 1 |
| Boi, L | 1 |
| Pisanu, A | 2 |
| Scerba, MT | 1 |
| Tweedie, D | 1 |
| Mulas, G | 2 |
| Fenu, S | 2 |
| Carboni, E | 2 |
| Spiga, S | 2 |
| Carta, AR | 6 |
| Gago, B | 1 |
| Rodríguez-Oroz, MC | 3 |
| Obeso, JA | 3 |
| Ferreira, NR | 1 |
| de Oliveira-Tavares, D | 1 |
| de Aguiar, D | 1 |
| da Silva, CA | 1 |
| Aguiar, AS | 1 |
| Moreira, EL | 1 |
| Hoeller, AA | 1 |
| Oliveira, PA | 1 |
| Córdova, FM | 1 |
| Glaser, V | 1 |
| Walz, R | 1 |
| Cunha, RA | 1 |
| Leal, RB | 1 |
| Latini, A | 1 |
| Prediger, RD | 1 |
| Mabrouk, OS | 1 |
| Mela, F | 4 |
| Calcagno, M | 1 |
| Budri, M | 1 |
| Viaro, R | 1 |
| Dekundy, A | 5 |
| Parsons, CG | 2 |
| Auberson, YP | 1 |
| Suárez, LM | 2 |
| Caramés, JM | 1 |
| Taravini, IR | 4 |
| Solís, JM | 1 |
| Szawka, RE | 1 |
| da-Silva, CA | 3 |
| Anselmo-Franci, J | 2 |
| Romano-Dutra, AC | 1 |
| Guimaraes, FS | 2 |
| Jones, N | 1 |
| Bleickardt, C | 1 |
| Mullins, D | 1 |
| Parker, E | 1 |
| Hodgson, R | 1 |
| Smith, GA | 3 |
| Heuer, A | 4 |
| Klein, A | 1 |
| Vinh, NN | 1 |
| Lopez, S | 1 |
| Bonito-Oliva, A | 2 |
| Pallottino, S | 1 |
| Acher, F | 1 |
| Lisci, C | 1 |
| Collu, M | 1 |
| Devoto, P | 2 |
| Lindenbach, D | 5 |
| Goldenberg, AA | 3 |
| Kampton, E | 2 |
| Dell'isola, R | 1 |
| Katzman, AC | 1 |
| González-Aparicio, R | 1 |
| Gutiérrez-Valdez, AL | 1 |
| García-Ruiz, R | 1 |
| Anaya-Martínez, V | 1 |
| Torres-Esquivel, C | 1 |
| Espinosa-Villanueva, J | 1 |
| Reynoso-Erazo, L | 1 |
| Tron-Alvarez, R | 1 |
| Aley-Medina, P | 1 |
| Sánchez-Betancourt, J | 1 |
| Montiel-Flores, E | 1 |
| Avila-Costa, MR | 1 |
| Ueno, T | 1 |
| Yamada, J | 1 |
| Arai, A | 1 |
| Migita, K | 1 |
| Baba, M | 1 |
| Ueno, S | 1 |
| Kelsey, JE | 1 |
| Neville, C | 1 |
| Zhang, QJ | 1 |
| Wang, T | 3 |
| Thornton, E | 1 |
| Hassall, MM | 1 |
| Corrigan, F | 1 |
| Vink, R | 1 |
| Doo, AR | 1 |
| Kim, SN | 1 |
| Hahm, DH | 1 |
| Yoo, HH | 1 |
| Park, JY | 2 |
| Lee, H | 1 |
| Jeon, S | 1 |
| Park, SU | 1 |
| Shin, E | 3 |
| Rogers, JT | 1 |
| Cerovic, M | 1 |
| Bagetta, V | 5 |
| Pendolino, V | 5 |
| Hardingham, N | 1 |
| Papale, A | 1 |
| Marchisella, F | 1 |
| Giampà, C | 3 |
| Mellstrom, B | 1 |
| Vallejo, M | 1 |
| Naranjo, JR | 1 |
| Zhao, R | 1 |
| Lu, W | 1 |
| Fang, X | 1 |
| Guo, L | 2 |
| Yang, Z | 1 |
| Ye, N | 2 |
| Jia, J | 1 |
| Zheng, L | 2 |
| Zhao, B | 1 |
| Zhang, A | 2 |
| Zhen, X | 3 |
| Ko, WK | 2 |
| Martin-Negrier, ML | 1 |
| Crossman, AR | 5 |
| Huang, C | 1 |
| Kapitsa, IG | 2 |
| Ivanova, EA | 2 |
| Kokshenev, II | 2 |
| Nepoklonov, AV | 2 |
| Val'dman, EA | 2 |
| Voronina, TA | 2 |
| Engeln, M | 1 |
| Bastide, MF | 2 |
| Toulmé, E | 1 |
| Bourdenx, M | 1 |
| Doudnikoff, E | 3 |
| Gross, CE | 2 |
| Boué-Grabot, E | 1 |
| Pisani, A | 1 |
| Fernagut, PO | 2 |
| Papathanou, M | 2 |
| Jenner, P | 3 |
| Iravani, M | 1 |
| Jackson, M | 1 |
| Stockwell, K | 1 |
| Strang, I | 1 |
| Zeng, BY | 1 |
| McCreary, AC | 4 |
| Rose, S | 2 |
| Garrido-Gil, P | 1 |
| Dominguez-Meijide, A | 1 |
| Thiele, SL | 1 |
| Chen, B | 1 |
| Lo, C | 1 |
| Gertler, TS | 1 |
| Warre, R | 1 |
| Surmeier, JD | 1 |
| Nash, JE | 1 |
| Södersten, E | 1 |
| Vialou, V | 1 |
| LaPlant, Q | 1 |
| Watts, EL | 1 |
| Hansen, K | 1 |
| Nestler, EJ | 1 |
| Cavalcanti-Kiwiatkoviski, R | 1 |
| Carolino, RO | 1 |
| Alcacer, C | 2 |
| Charbonnier-Beaupel, F | 1 |
| Corvol, JC | 1 |
| Koprich, JB | 1 |
| Espinosa, MC | 1 |
| Reyes, MG | 1 |
| Hofmann, M | 1 |
| Danysz, W | 4 |
| Farré, D | 1 |
| Moreno, E | 1 |
| Reyes-Resina, I | 1 |
| Canet-Pons, J | 1 |
| Dopeso-Reyes, IG | 1 |
| Rico, AJ | 1 |
| Lluís, C | 1 |
| Mallol, J | 1 |
| Canela, EI | 1 |
| Cortés, A | 1 |
| Casadó, V | 1 |
| Lanciego, JL | 1 |
| de la Crompe, B | 1 |
| Mallet, N | 1 |
| Boraud, T | 1 |
| Martinez, AA | 1 |
| Morgese, MG | 3 |
| Macheda, T | 2 |
| Paquette, MA | 3 |
| Seillier, A | 1 |
| Cassano, T | 2 |
| Giuffrida, A | 5 |
| Ba, M | 1 |
| Kong, M | 1 |
| Ma, G | 1 |
| Iderberg, H | 4 |
| Varney, MA | 3 |
| Newman-Tancredi, A | 3 |
| Maslava, N | 2 |
| Thompson, AD | 1 |
| Bubser, M | 1 |
| Niswender, CM | 1 |
| Hopkins, CR | 2 |
| Lindsley, CW | 1 |
| Conn, PJ | 1 |
| Jones, CK | 1 |
| O'Malley, J | 1 |
| Rademacher, DJ | 1 |
| Sisson, KA | 1 |
| Paumier, KL | 1 |
| Gebremedhin, KG | 1 |
| Zhang, T | 1 |
| Shi, Q | 1 |
| Chen, Z | 1 |
| Tang, B | 1 |
| Bordia, T | 1 |
| McGregor, M | 1 |
| McIntosh, JM | 1 |
| Drenan, RM | 1 |
| Quik, M | 3 |
| Hallmark, J | 1 |
| Palumbo, N | 1 |
| Bhide, N | 3 |
| Conti, M | 1 |
| George, JA | 1 |
| Keber, U | 2 |
| Klietz, M | 2 |
| Carlsson, T | 6 |
| Oertel, WH | 1 |
| Weihe, E | 2 |
| Schäfer, MK | 2 |
| Höglinger, GU | 2 |
| Depboylu, C | 2 |
| Shin, KS | 1 |
| Zhao, TT | 1 |
| Park, KH | 1 |
| Hwang, BY | 1 |
| Lee, CK | 1 |
| Lee, MK | 1 |
| Chuan, Q | 1 |
| Urs, NM | 1 |
| Bido, S | 1 |
| Peterson, SM | 1 |
| Daigle, TL | 1 |
| Bass, CE | 1 |
| Gainetdinov, RR | 1 |
| Caron, MG | 1 |
| Zhao, H | 1 |
| Shi, H | 1 |
| Zhang, S | 1 |
| Zu, J | 1 |
| Zhang, W | 1 |
| Shen, X | 1 |
| Cavalcanti-Kiwiatkoski, R | 1 |
| Dos Santos-Pereira, M | 1 |
| Mitkovski, M | 1 |
| Kleven, MS | 1 |
| Koek, W | 1 |
| Bardin, L | 1 |
| Depoortère, R | 1 |
| Mengod, G | 1 |
| Cortés, R | 1 |
| Zhang, K | 1 |
| Chammas, C | 1 |
| Soghomonian, JJ | 2 |
| Paolone, G | 1 |
| Dupre, KB | 7 |
| Ndlovu, BC | 1 |
| Daniels, WM | 1 |
| Mabandla, MV | 1 |
| Cruz, AV | 1 |
| McCoy, AJ | 1 |
| Delaville, C | 1 |
| Gerber, CM | 1 |
| Eyring, KW | 1 |
| Walters, JR | 1 |
| Mineo, D | 1 |
| Vannelli, A | 1 |
| Cacace, F | 1 |
| Mancini, M | 1 |
| di Maio, A | 1 |
| Sagarduy, A | 2 |
| Llorente, J | 1 |
| Gangarossa, G | 1 |
| Guzman, M | 1 |
| Prado, VF | 1 |
| Prado, MA | 1 |
| Daumas, S | 1 |
| El Mestikawy, S | 1 |
| Valjent, E | 3 |
| Navailles, S | 1 |
| De Deurwaerdère, P | 2 |
| Park, TS | 1 |
| Hu, R | 1 |
| Cheng, J | 1 |
| Li, L | 1 |
| Fan, Q | 1 |
| Wu, N | 2 |
| Gan, J | 1 |
| Zhou, M | 1 |
| McConnell, GC | 1 |
| So, RQ | 1 |
| Grill, WM | 1 |
| Smith, LM | 1 |
| Parr-Brownlie, LC | 1 |
| Duncan, EJ | 1 |
| Black, MA | 1 |
| Gemmell, NJ | 1 |
| Dearden, PK | 1 |
| Reynolds, JN | 1 |
| Lin, JY | 1 |
| Wang, MH | 1 |
| Zhang, Y | 1 |
| Zhang, SF | 1 |
| Wang, XJ | 1 |
| Liu, ZG | 1 |
| Bariotto-Dos-Santos, KD | 1 |
| Sgroi, S | 1 |
| Capper-Loup, C | 1 |
| Paganetti, P | 1 |
| Kaelin-Lang, A | 1 |
| Tomas, D | 1 |
| Stanic, D | 1 |
| Chua, HK | 1 |
| White, K | 1 |
| Boon, WC | 1 |
| Horne, M | 1 |
| Palafox-Sánchez, V | 1 |
| Mendieta, L | 1 |
| Ramírez-García, G | 1 |
| Candalija, A | 1 |
| Aguilera, J | 1 |
| Limón, ID | 1 |
| Aldrin-Kirk, P | 1 |
| Wang, G | 1 |
| Mattsson, B | 2 |
| Lundblad, M | 8 |
| Björklund, T | 1 |
| Figge, DA | 1 |
| Eskow Jaunarajs, KL | 3 |
| Standaert, DG | 2 |
| Bez, F | 1 |
| Chiu, WH | 1 |
| Sebastianutto, I | 1 |
| Aguado, C | 1 |
| Lujan, R | 1 |
| Smith, ES | 1 |
| Hardy, GA | 1 |
| Schallert, T | 1 |
| Lee, HJ | 1 |
| Cossu, G | 1 |
| Pillai, E | 1 |
| Simbula, G | 1 |
| Jadžić, D | 1 |
| Angius, F | 1 |
| Spolitu, S | 1 |
| Batetta, B | 1 |
| Lecca, D | 1 |
| A Figge, D | 1 |
| Frau, L | 3 |
| Pontis, S | 3 |
| Larramendy, C | 2 |
| Saborido, MD | 1 |
| Ferrario, JE | 2 |
| Gershanik, OS | 3 |
| Fiorentini, C | 3 |
| Busi, C | 2 |
| Spano, P | 2 |
| Missale, C | 3 |
| Barnum, CJ | 5 |
| Eskow, KL | 4 |
| Dupre, K | 1 |
| Blandino, P | 1 |
| Deak, T | 2 |
| Giorgi, M | 1 |
| D'Angelo, V | 1 |
| Esposito, Z | 1 |
| Nuccetelli, V | 1 |
| Sorge, R | 1 |
| Martorana, A | 1 |
| Stefani, A | 1 |
| Bernardi, G | 2 |
| Sancesario, G | 1 |
| Schmidt, WJ | 2 |
| Lebsanft, H | 1 |
| Heindl, M | 1 |
| Gerlach, M | 4 |
| Gruenblatt, E | 1 |
| Riederer, P | 4 |
| Mayerhofer, A | 1 |
| Scheller, DK | 2 |
| Valastro, B | 1 |
| Quack, G | 1 |
| Schuster, S | 1 |
| Rylander, D | 3 |
| Berthet, A | 1 |
| Aubert, I | 1 |
| Ittrich, C | 1 |
| Bloch, B | 1 |
| Surmeier, DJ | 1 |
| Marti, M | 2 |
| Trapella, C | 1 |
| Winkler, C | 7 |
| Kirik, D | 4 |
| Monville, C | 2 |
| Torres, EM | 2 |
| Pekarik, V | 1 |
| Krolewski, DM | 1 |
| Walker, PD | 4 |
| Visanji, NP | 1 |
| Johnston, T | 1 |
| Reyes, G | 1 |
| Buck, K | 5 |
| Ferger, B | 5 |
| Aguilar, E | 4 |
| Bartoszyk, GD | 2 |
| Kääriäinen, TM | 1 |
| García-Horsman, JA | 1 |
| Piltonen, M | 1 |
| Männistö, PT | 1 |
| Echeverry, MB | 1 |
| Vercammen, L | 1 |
| Brundin, P | 3 |
| Pérez-Rial, S | 1 |
| García-Gutiérrez, MS | 1 |
| Molina, JA | 1 |
| Pérez-Nievas, BG | 1 |
| Ledent, C | 1 |
| Leiva, C | 1 |
| Leza, JC | 1 |
| Manzanares, J | 1 |
| Darmopil, S | 1 |
| Martín, AB | 2 |
| De Diego, IR | 1 |
| Ares, S | 1 |
| Lacombe, E | 1 |
| Khaindrava, V | 1 |
| Melon, C | 2 |
| Oueslati, A | 1 |
| Kerkerian-Le Goff, L | 2 |
| Salin, P | 1 |
| Jaunarajs, KL | 1 |
| Steiniger, A | 1 |
| Klioueva, A | 2 |
| Moore, A | 1 |
| Kelly, C | 1 |
| Jiménez, A | 1 |
| Yamamoto, N | 1 |
| Brown, AR | 1 |
| Hu, B | 1 |
| Antle, MC | 1 |
| Teskey, GC | 1 |
| Pérez, V | 1 |
| Rubio, A | 1 |
| Barbanoj, M | 1 |
| Leaver, KR | 1 |
| Allbutt, HN | 1 |
| Creber, NJ | 1 |
| Kassiou, M | 1 |
| Henderson, JM | 1 |
| Brocco, M | 1 |
| Voehringer, P | 2 |
| Andersson, DR | 1 |
| Lagerkvist, S | 1 |
| Nissbrandt, H | 2 |
| Anderson, AM | 1 |
| Lewis, JR | 1 |
| Meshul, CK | 2 |
| Johnson, SW | 2 |
| Paul Berger, S | 1 |
| Gil, S | 1 |
| Park, C | 1 |
| Lee, J | 2 |
| Koh, H | 1 |
| O'Sullivan, DB | 1 |
| Harrison, PT | 1 |
| Sullivan, AM | 1 |
| Li, H | 1 |
| Baishen, R | 1 |
| Kobylecki, C | 2 |
| Guan, Q | 2 |
| Liu, X | 1 |
| He, Y | 2 |
| Jin, L | 1 |
| Zhao, L | 1 |
| Manyam, BV | 1 |
| Belujon, P | 1 |
| Lodge, DJ | 1 |
| Grace, AA | 1 |
| Matsui, H | 1 |
| Ito, H | 1 |
| Taniguchi, Y | 1 |
| Inoue, H | 1 |
| Takeda, S | 1 |
| Takahashi, R | 1 |
| Fang, C | 1 |
| Yin, J | 1 |
| Xu, Z | 1 |
| Xu, H | 1 |
| Zhou, H | 1 |
| Gao, C | 1 |
| Rangel-Barajas, C | 1 |
| Silva, I | 1 |
| Lopéz-Santiago, LM | 1 |
| Aceves, J | 1 |
| Erlij, D | 1 |
| Florán, B | 1 |
| Xiao, D | 2 |
| Cassin, JJ | 1 |
| Healy, B | 1 |
| Burdett, TC | 1 |
| Chen, JF | 4 |
| Fredholm, BB | 1 |
| Schwarzschild, MA | 4 |
| Parent, M | 1 |
| O'Sullivan, SS | 1 |
| Dovero, S | 1 |
| Lees, AJ | 1 |
| Descarries, L | 1 |
| Spinnewyn, B | 2 |
| Charnet, C | 1 |
| Cornet, S | 1 |
| Roubert, V | 1 |
| Chabrier, PE | 2 |
| Auguet, M | 2 |
| Mautino, G | 1 |
| Marin, JG | 1 |
| Rocher, MN | 1 |
| Grandoulier, AS | 1 |
| Ferrandis, E | 1 |
| Gravius, A | 1 |
| Hechenberger, M | 1 |
| Pietraszek, M | 1 |
| Nagel, J | 1 |
| Tober, C | 1 |
| van der Elst, M | 1 |
| Gil, SJ | 1 |
| Park, CH | 1 |
| Lee, JE | 1 |
| Minn, YK | 1 |
| Koh, HC | 1 |
| Paillè, V | 2 |
| Di Filippo, M | 1 |
| Fusco, FR | 1 |
| Sgobio, C | 3 |
| Grünblatt, E | 1 |
| Finberg, JP | 1 |
| Gluzman, Z | 1 |
| Reshef, M | 1 |
| Loboda, Y | 1 |
| Mohsen, U | 1 |
| Bressler-Stramer, T | 1 |
| Miari, R | 1 |
| Gepstein, L | 1 |
| Marom, S | 1 |
| Feld, Y | 1 |
| Daly, CS | 1 |
| Huang, LZ | 2 |
| Campos, C | 1 |
| Ly, J | 1 |
| Ivy Carroll, F | 1 |
| Dean, O | 1 |
| van den Buuse, M | 2 |
| Recchia, A | 1 |
| Popovic, N | 1 |
| Andersson, D | 1 |
| Button, T | 1 |
| Savage, LM | 1 |
| Wolf, W | 1 |
| Nevalainen, N | 1 |
| Af Bjerkén, S | 1 |
| Gerhardt, GA | 1 |
| Strömberg, I | 1 |
| Alachkar, A | 1 |
| Jones, OT | 1 |
| Zhang, H | 2 |
| Zhou, S | 1 |
| Gao, B | 1 |
| García, J | 3 |
| Döbrössy, M | 2 |
| Nikkhah, G | 2 |
| McCreary, A | 1 |
| Grady, SR | 1 |
| Young, CK | 1 |
| Whishaw, IQ | 1 |
| Bland, BH | 1 |
| Errico, F | 2 |
| Vitucci, D | 1 |
| Romano, R | 1 |
| Marinucci, S | 1 |
| Yin, LL | 1 |
| Geng, XC | 1 |
| Zhu, XZ | 1 |
| Surrena, MA | 1 |
| Tignor, S | 1 |
| Walters, H | 1 |
| Chagniel, L | 1 |
| Robitaille, C | 1 |
| Lebel, M | 1 |
| Cyr, M | 1 |
| Sander, SE | 1 |
| Lemm, C | 1 |
| Lange, N | 1 |
| Hamann, M | 1 |
| Richter, A | 1 |
| Nahimi, A | 1 |
| Høltzermann, M | 1 |
| Landau, AM | 1 |
| Simonsen, M | 1 |
| Jakobsen, S | 1 |
| Alstrup, AK | 1 |
| Vang, K | 1 |
| Møller, A | 1 |
| Wegener, G | 1 |
| Gjedde, A | 1 |
| Doudet, DJ | 1 |
| Subramaniam, S | 1 |
| Mealer, RG | 1 |
| Kim, S | 1 |
| Barrow, R | 1 |
| Shahani, N | 1 |
| Tyagi, R | 1 |
| Snyder, SH | 1 |
| Martinez, A | 1 |
| Trabace, L | 1 |
| Maranis, S | 1 |
| Stamatis, D | 1 |
| Tsironis, C | 2 |
| Konitsiotis, S | 2 |
| Bennouar, KE | 1 |
| Uberti, MA | 1 |
| Bacolod, MD | 1 |
| Jimenez, HN | 1 |
| Cajina, M | 1 |
| Doller, D | 1 |
| Gubellini, P | 1 |
| Gaven, F | 1 |
| Halley, P | 1 |
| Azkona, G | 1 |
| Sanchez-Pernaute, R | 1 |
| Breger, LS | 1 |
| Rodi, D | 1 |
| Guerrini, R | 1 |
| Simonato, M | 1 |
| Halje, P | 1 |
| Tamtè, M | 1 |
| Richter, U | 1 |
| Mohammed, M | 1 |
| Petersson, P | 1 |
| Chen, Y | 1 |
| Hong, X | 1 |
| Yuan, W | 1 |
| Del Papa, G | 1 |
| Seeger-Armbruster, S | 1 |
| von Ameln-Mayerhofer, A | 1 |
| Savoia, P | 1 |
| Savoldi, D | 1 |
| Barbon, A | 1 |
| Morin, N | 1 |
| Jourdain, VA | 1 |
| Di Paolo, T | 1 |
| Pioli, EY | 1 |
| Murray, TK | 1 |
| Messenger, MJ | 1 |
| Ward, MA | 1 |
| Woodhouse, S | 1 |
| Osborne, DJ | 1 |
| Duty, S | 1 |
| O'Neill, MJ | 1 |
| Klintenberg, R | 1 |
| Gunne, L | 1 |
| Andrén, PE | 1 |
| Oh, JD | 3 |
| Bibbiani, F | 3 |
| Chase, TN | 4 |
| Périer, C | 1 |
| Tolosa, E | 2 |
| Hirsch, EC | 1 |
| Vaudano, E | 1 |
| Kamdar, DP | 1 |
| Ferrer, B | 1 |
| Asbrock, N | 1 |
| Kathuria, S | 1 |
| Piomelli, D | 1 |
| Petzer, JP | 1 |
| Castagnoli, N | 1 |
| Fredduzzi, S | 1 |
| Bastia, E | 2 |
| Yu, L | 1 |
| Ongini, E | 1 |
| Kase, H | 1 |
| Aoyama, S | 1 |
| Ichimura, M | 1 |
| Ikeda, K | 1 |
| Ishii, A | 1 |
| Kanda, T | 1 |
| Koga, K | 1 |
| Koike, N | 1 |
| Kurokawa, M | 1 |
| Kuwana, Y | 1 |
| Mori, A | 1 |
| Nakamura, J | 1 |
| Nonaka, H | 1 |
| Ochi, M | 1 |
| Saki, M | 1 |
| Shimada, J | 1 |
| Shindou, T | 1 |
| Shiozaki, S | 1 |
| Suzuki, F | 1 |
| Takeda, M | 1 |
| Yanagawa, K | 1 |
| Richardson, PJ | 1 |
| Bedard, P | 1 |
| Borrelli, E | 1 |
| Hauser, RA | 1 |
| Chalon, S | 1 |
| Delfino, MA | 1 |
| Stefano, AV | 1 |
| Lindgren, H | 1 |
| Linazasoro, G | 1 |
| Håkansson, K | 1 |
| Taylor, JL | 2 |
| Pavón, N | 1 |
| Mendialdua, A | 1 |
| Sgambato-Faure, V | 1 |
| Buggia, V | 1 |
| Gilbert, F | 1 |
| Benabid, AL | 1 |
| Berger, F | 1 |
| Yamada, K | 1 |
| Goto, S | 1 |
| Kaji, R | 1 |
| Kuratsu, J | 1 |
| Rizzetti, MC | 1 |
| Bontempi, S | 1 |
| Collo, G | 1 |
| Fadda, F | 1 |
| Kuhn, DM | 1 |
| Wood, MD | 1 |
| Scott, C | 1 |
| Clarke, K | 1 |
| Westaway, J | 1 |
| Davies, CH | 1 |
| Reavill, C | 1 |
| Hill, M | 1 |
| Rourke, C | 1 |
| Newson, M | 1 |
| Jones, DN | 1 |
| Forbes, IT | 1 |
| Gribble, A | 1 |
| Westin, JE | 1 |
| Gardi, J | 1 |
| Nyengaard, JR | 1 |
| Mohapel, P | 1 |
| Smith, CP | 1 |
| Collins, MA | 1 |
| Avila, I | 1 |
| Kuan, WL | 2 |
| Lin, R | 1 |
| Tyers, P | 1 |
| Barker, RA | 2 |
| Xu, YH | 1 |
| Benn, CL | 1 |
| Cha, JH | 1 |
| Peterson, TS | 1 |
| Fulceri, F | 1 |
| Biagioni, F | 1 |
| Ferrucci, M | 1 |
| Lazzeri, G | 1 |
| Bartalucci, A | 1 |
| Galli, V | 1 |
| Ruggieri, S | 1 |
| Paparelli, A | 1 |
| Fornai, F | 1 |
| Delfino, M | 1 |
| Kalisch, R | 1 |
| Czisch, M | 1 |
| Ricatti, J | 1 |
| Trenkwalder, C | 1 |
| Auer, DP | 1 |
| Ma, L | 1 |
| Wang, F | 1 |
| Chen, J | 1 |
| Greengard, P | 1 |
| Zhan, Q | 1 |
| Tan, L | 1 |
| Lane, E | 1 |
| Dunnett, S | 1 |
| Cuomo, V | 1 |
| Levandis, G | 1 |
| Bazzini, E | 1 |
| Armentero, MT | 1 |
| Nappi, G | 1 |
| Barone, I | 1 |
| Angela Cenci, M | 1 |
| Zhao, JW | 1 |
| Gomez-Ramirez, J | 1 |
| Visanji, N | 1 |
| Brudney, EG | 1 |
| Putterman, DB | 1 |
| Berger, SP | 1 |
| Lucia, F | 1 |
| Annalisa, P | 1 |
| Silvia, P | 1 |
| Simola, N | 1 |
| Nicola, S | 1 |
| Schintu, N | 1 |
| Nicoletta, S | 1 |
| Micaela, M | 1 |
| Offermeier, J | 1 |
| van Rooyen, JM | 1 |
| Huang, NY | 2 |
| Kostrzewa, RM | 3 |
| Neisewander, JL | 1 |
| Castañeda, E | 1 |
| Davis, DA | 1 |
| Elson, HJ | 1 |
| Sussman, AN | 1 |
| Li, C | 1 |
| Perry, KW | 1 |
| Fuller, RW | 1 |
| Neal-Beliveau, BS | 1 |
| Joyce, JN | 1 |
| Henry, B | 1 |
| Lee, CS | 1 |
| Saka, E | 1 |
| Elibol, B | 1 |
| Erdem, S | 1 |
| Dalkara, T | 1 |
| Lindner, MD | 1 |
| Cain, CK | 1 |
| Plone, MA | 1 |
| Frydel, BR | 1 |
| Blaney, TJ | 1 |
| Emerich, DF | 1 |
| Hoane, MR | 1 |
| Willis, GL | 1 |
| Armstrong, SM | 1 |
| Van Kampen, JM | 1 |
| Stoessl, AJ | 1 |
| Chesselet, MF | 1 |
| Johansson, PA | 1 |
| Andersson, M | 2 |
| Andersson, KE | 1 |
| Olds, ME | 1 |
| Jacques, DB | 1 |
| Kopyov, O | 1 |
| Van De Witte, SV | 1 |
| Groenewegen, HJ | 1 |
| Voorn, P | 1 |
| Wierup, N | 1 |
| Gong, L | 1 |
| Carey, RJ | 2 |
| Jolicoeur, FB | 1 |
| Rivest, R | 1 |
| Drumheller, A | 1 |
| Schwarting, RK | 1 |
| Bonatz, AE | 1 |
| Huston, JP | 1 |
| Orikasa, S | 1 |
| Sloley, BD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the Safety and Tolerability of Intraputamenal Transplantation of Human Embryonic Stem Cell Derived Dopaminergic Cells for Parkinson's Disease (STEM-PD Product)[NCT05635409] | Phase 1 | 8 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia and Healthy Age Matched Controls; [11C]Yohimbine and [11C]MeNER PET[NCT02578849] | 45 participants (Anticipated) | Observational | 2012-01-31 | Recruiting | |||
| Mucuna Pruriens Therapy in Parkinson's Disease: a Double-blind, Placebo-controlled, Randomized, Crossover Study.[NCT02680977] | Phase 2 | 18 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Preventing Levodopa Induced Dyskinesia in Parkinson?s Disease With Statins[NCT04064294] | 120 participants (Anticipated) | Observational | 2019-06-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for oxidopamine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodege | 2022 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodege | 2022 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodege | 2022 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodege | 2022 |
Impaired cognitive and motor function are coincident with L-DOPA-induced dyskinesia in a model of Parkinson's disease.
Topics: Animals; Cognition; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Lev | 2023 |
Research advances on L-DOPA-induced dyskinesia: from animal models to human disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; M | 2020 |
Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited.
Topics: Animals; Antiparkinson Agents; Cholinergic Antagonists; Corpus Striatum; Disease Models, Animal; Dys | 2021 |
Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; | 2018 |
Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Park | 2014 |
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence.
Topics: Animals; Antiparkinson Agents; Behavior; Brain Chemistry; Corpus Striatum; Disease Models, Animal; D | 2008 |
Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; | 2008 |
Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; L | 2011 |
The interhemispheric connections of the striatum: Implications for Parkinson's disease and drug-induced dyskinesias.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; N | 2012 |
Modeling dyskinesia in animal models of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; MPTP Poisoning; Oxi | 2014 |
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus S | 2003 |
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Dise | 2004 |
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Dr | 2008 |
334 other studies available for oxidopamine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Medial Foreb | 2021 |
Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; GABAergic N | 2021 |
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease.
Topics: Animals; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2021 |
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Oxidopam | 2021 |
Autoradiographic labelling of 5-HT
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Ondansetr | 2022 |
Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonis | 2022 |
Striatal Neuronal Ensembles Reveal Differential Actions of Amantadine and Clozapine to Ameliorate Mice L-DOPA-Induced Dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Calcium; Clozapine; Corpus Striatum; Disease Models, Anim | 2022 |
Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia.
Topics: Amphetamines; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Indu | 2022 |
The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitat | 2022 |
D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice.
Topics: Animals; Antiparkinson Agents; Cholinergic Agents; Corpus Striatum; Disease Models, Animal; Dyskines | 2022 |
Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice | 2022 |
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine Plasma Membrane Transport Proteins; | 2022 |
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Le | 2022 |
Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Buspirone; Dyskinesia, Drug-Induced; Levodopa; Oxazolidin | 2022 |
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; | 2023 |
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; | 2023 |
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; | 2023 |
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; | 2023 |
Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; | 2023 |
ONO-2506 Can Delay Levodopa-induced Dyskinesia in the Early Stage.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Le | 2023 |
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dutasteride; Dyskinesia, Dru | 2023 |
PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Delayed-Action Preparations; Disease Models, Animal; Dopamine; Dyskin | 2023 |
The Dynamics of Dopamine D
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Neuron | 2023 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Ind | 2023 |
Chronic H
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Ac | 2023 |
Amphiregulin blockade decreases the levodopa-induced dyskinesia in a 6-hydroxydopamine Parkinson's disease mouse model.
Topics: Amphiregulin; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levod | 2023 |
Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; Humans; Hyperkinesis; L | 2023 |
BDNF/TrkB pathway activation in D1 receptor-expressing striatal projection neurons plays a protective role against L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dopamine; Dopamin | 2023 |
Brainstem Modulates Parkinsonism-Induced Orofacial Sensorimotor Dysfunctions.
Topics: Animals; Antiparkinson Agents; Brain Stem; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug | 2023 |
Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; gamma-Aminobut | 2023 |
Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxid | 2023 |
Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; | 2019 |
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Corpus Striatum; Dopami | 2020 |
Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; M | 2020 |
D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induce | 2020 |
The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia.
Topics: Animals; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-In | 2020 |
Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
Topics: Amantadine; Animals; Antiparkinson Agents; Bridged Bicyclo Compounds; Corpus Striatum; Dyskinesia, D | 2020 |
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: Administration, Oral; Amantadine; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; D | 2020 |
Genetic lack of histamine upregulates dopamine neurotransmission and alters rotational behavior but not levodopa-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Le | 2020 |
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Topics: Aged; Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nuclear Re | 2020 |
L-DOPA-elicited abnormal involuntary movements in the rats damaged severely in substantia nigra by 6-hydroxydopamine.
Topics: Animals; Apomorphine; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Rats; Substantia Ni | 2020 |
Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; | 2020 |
BDNF Overexpression Increases Striatal D3 Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia.
Topics: Animals; Benzazepines; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; D | 2020 |
Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Globus Pallidus; Levod | 2020 |
Globus pallidus, but not entopeduncular nucleus, 6-OHDA-induced lesion attenuates L-Dopa-induced dyskinesia in the rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Entopedun | 2020 |
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
Topics: Allosteric Regulation; Animals; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; | 2020 |
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Ind | 2020 |
The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-I | 2021 |
The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cell Transplantation; Dopaminergic | 2021 |
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopami | 2021 |
Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; G | 2021 |
Involvement of Autophagy in Levodopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Autophagy; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug- | 2021 |
Novel Interactions Involving the Mas Receptor Show Potential of the Renin-Angiotensin system in the Regulation of Microglia Activation: Altered Expression in Parkinsonism and Dyskinesia.
Topics: Angiotensin II; Animals; Corpus Striatum; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Male; Mice | 2021 |
Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.
Topics: Analgesics; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induce | 2021 |
Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation Mediators; In | 2021 |
Striatal ΔFosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Hu | 2021 |
Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Doxycycline; Dyskinesia, Dru | 2021 |
Marijuana improved motor impairments and changes in synaptic plasticity-related molecules in the striatum in 6-OHDA-treated rats.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Cannabinoid Receptor Agonists; Disease Models, Animal; | 2021 |
The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian | 2021 |
Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Benzimida | 2021 |
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Calcium-Binding Proteins; Caudate | 2021 |
Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.
Topics: Animals; Antiparkinson Agents; Armadillo Domain Proteins; Catechol O-Methyltransferase; Cell Adhesio | 2017 |
Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
Topics: Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dyskinesia, D | 2017 |
Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Dru | 2017 |
Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
Topics: Animals; Anti-Bacterial Agents; Ceftriaxone; Disease Models, Animal; Dopamine Agents; Dyskinesia, Dr | 2017 |
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dyskinesia, Drug- | 2017 |
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Corpus | 2017 |
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Topics: Adrenergic Agents; Analgesics, Opioid; Animals; Benzamides; Disease Models, Animal; Dose-Response Re | 2018 |
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetamides; Animals; Antiparkinson Agent | 2018 |
CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cor | 2018 |
Correlation between dopamine receptor D2 expression and presence of abnormal involuntary movements in Wistar rats with hemiparkinsonism and dyskinesia.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprag | 2021 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Ther | 2018 |
Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
Topics: Animals; Antiparkinson Agents; Apomorphine; Arachidonic Acids; Biomarkers; Cannabinoid Receptor Agon | 2018 |
Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation; Levodopa; Ma | 2018 |
Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
Topics: Administration, Inhalation; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Rel | 2018 |
Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain; Central Nervous System Stimulants; Dopamine; Dopa | 2018 |
Effects of histone acetyltransferase inhibitors on L-DOPA-induced dyskinesia in a murine model of Parkinson's disease.
Topics: Anacardic Acids; Animals; Antiparkinson Agents; Curcumin; Cytoskeletal Proteins; Drug Evaluation, Pr | 2018 |
Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Drug Repositioning; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; | 2019 |
Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice.
Topics: Acupuncture Therapy; Animals; Aphakia; Dyskinesia, Drug-Induced; Gene Expression Regulation; Homeodo | 2019 |
Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats.
Topics: Animals; Behavior, Animal; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus | 2018 |
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dizocilpine Maleate; Drug Synergism; Dyskinesia, Drug-I | 2018 |
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopam | 2018 |
Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model.
Topics: Animals; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dyskinesia, Drug-Induc | 2019 |
Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkepha | 2018 |
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
Topics: Animals; Anticonvulsants; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopam | 2019 |
Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.
Topics: Activins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Disease Progressio | 2019 |
Chronic administration of the histamine H
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Histamine Agonists; Imidazoles; Levodopa; Male; | 2019 |
Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; La | 2019 |
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Calcium Channels; Disease Models, Animal; Dyskines | 2019 |
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Angiogenesis Inhibitors; Animals; Antiparkinson Agents; Cytokines; Dyskinesia, Drug-Induced; Immunol | 2019 |
l-dopa-induced dyskinesias in unilateral 6-hydroxydopamine-lesioned rats are not modified by excitotoxic lesion of the entopeduncular nucleus and substantia nigra pars reticulata.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Mov | 2013 |
Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Indazoles; Levodopa; Male; | 2013 |
Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
Topics: Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dyskinesia, Dr | 2013 |
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Ac | 2013 |
L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Cerebral | 2014 |
Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitor | 2014 |
A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Analysis of Variance; Animals; Anti-Dyskinesia | 2013 |
Amphetamine-induced dyskinesia in the transplanted hemi-Parkinsonian mouse.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Cell Transplantation; Corpus Striatum | 2012 |
Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Aminobutyrates; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Dise | 2011 |
5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Topics: 5-Hydroxytryptophan; Adrenergic Agents; Animals; Caudate Nucleus; Disease Models, Animal; Dopamine; | 2013 |
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Citalopram; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Acti | 2014 |
Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dysk | 2014 |
The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Administration, Oral; Animals; Cannabinoid Receptor Antagonists; Corpus Striatum; Dihydroxyphenylala | 2013 |
Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dendritic Spines; Dyskinesia, Drug-Induced; Excitatory Postsynaptic P | 2014 |
The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.
Topics: Animals; Anti-Bacterial Agents; Antiparkinson Agents; Ceftriaxone; Central Nervous System Agents; Dy | 2014 |
Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Endocan | 2014 |
The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Dose-Response Relationship, | 2014 |
Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Gastrodia; Lev | 2014 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benz | 2014 |
Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine | 2014 |
Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Butadienes; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, D | 2015 |
Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
Topics: Acetylation; Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Dynorphins; Dyskines | 2015 |
(6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Aporphines; Base Sequence; Disease Models, Animal; DNA Primers; Dopam | 2014 |
RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephali | 2014 |
L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzylamines; Chromatography, High Pressure Liquid | 2014 |
[Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].
Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Ma | 2014 |
Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Daunorubicin; Disease Models, Animal; Dyskinesia, Drug-Induced; Levod | 2016 |
The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats.
Topics: Animals; Dyskinesia, Drug-Induced; Dyskinesias; Histamine Agonists; Imidazoles; Levodopa; Male; Oxid | 2014 |
Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
Topics: Adrenergic Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Antiparkinson Agents; Benzimida | 2014 |
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.
Topics: Animals; Animals, Newborn; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine A | 2014 |
A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB Expression.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; | 2016 |
Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
Topics: Animals; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Nitric Oxide Syntha | 2015 |
Mitogen- and stress-activated protein kinase 1 is required for specific signaling responses in dopamine-denervated mouse striatum, but is not necessary for L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dihydroxyphenylalanine; Dopaminergic Neurons; Dyskin | 2014 |
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relations | 2015 |
Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.
Topics: Acetamides; Animals; Brain; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Thera | 2015 |
Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Corpus Striatu | 2015 |
Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.
Topics: Animals; Corpus Striatum; Daunorubicin; Deoxyglucose; Disease Models, Animal; Dyskinesia, Drug-Induc | 2016 |
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Ea | 2015 |
Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models.
Topics: Animals; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Female; In | 2015 |
Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesi | 2015 |
Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Catalepsy; Dyskinesia, Drug-Induced; Excitatory Amino | 2015 |
Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration.
Topics: Aging; Amphetamine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Ph | 2015 |
Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; | 2015 |
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Diseas | 2015 |
Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinso | 2015 |
Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Amphetamine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Dru | 2015 |
Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskines | 2015 |
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Citalopram; Disease Models, Animal; Dyskinesia, | 2015 |
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; | 2015 |
Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dopamine; Dop | 2015 |
Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?
Topics: Animals; Calbindins; Cyclooxygenase 2; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Dr | 2015 |
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Drug Int | 2015 |
From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; F | 2015 |
Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
Topics: Animals; Antiparkinson Agents; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Antag | 2015 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; | 2015 |
Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
Topics: AIDS-Related Complex; Animals; Benzazepines; Disease Models, Animal; Dopamine Agents; Dyskinesia, Dr | 2015 |
Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.
Topics: Adrenergic Agents; Age Factors; Animals; Animals, Newborn; Antiparkinson Agents; Catalase; Disease M | 2016 |
Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzazepines; Disease Models, Animal; Dopamine Agon | 2016 |
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Sig | 2016 |
Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.
Topics: Action Potentials; Adrenergic Agents; Adrenergic Uptake Inhibitors; Animals; Buspirone; Desipramine; | 2016 |
Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia.
Topics: Amino Acid Transport Systems, Acidic; Animals; Antiparkinson Agents; Cell Count; Cell Size; Choline | 2016 |
Coherence of neuronal firing of the entopeduncular nucleus with motor cortex oscillatory activity in the 6-OHDA rat model of Parkinson's disease with levodopa-induced dyskinesias.
Topics: Action Potentials; Animals; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Motor | 2016 |
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relati | 2016 |
The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA lesioned rats.
Topics: Animals; Dopamine Agents; Dorsal Raphe Nucleus; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Rat | 2016 |
Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats.
Topics: Action Potentials; Animals; Brain; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesia, | 2016 |
Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
Topics: Animals; Antigens, Differentiation; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dy | 2016 |
Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
Topics: Animals; Dyskinesia, Drug-Induced; Female; Levodopa; Nerve Tissue Proteins; Oxidopamine; Parkinsonia | 2016 |
Failure to suppress low-frequency neuronal oscillatory activity underlies the reduced effectiveness of random patterns of deep brain stimulation.
Topics: Action Potentials; Animals; Central Nervous System Stimulants; Deep Brain Stimulation; Dopamine D2 R | 2016 |
L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum.
Topics: Amino Acids; Animals; Aspartic Acid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Forelimb; | 2016 |
Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Cytoskeleton; Drug Combinations; Dyskin | 2016 |
Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Cyclic AMP-Dependent Protein Ki | 2016 |
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Topics: Amantadine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, | 2016 |
Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, | 2016 |
Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease.
Topics: Animals; Behavior, Animal; Brain; Cell Line; Cell- and Tissue-Based Therapy; Disease Models, Animal; | 2016 |
Effect of the C-terminal domain of the heavy chain of tetanus toxin on dyskinesia caused by levodopa in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Cell Death; Corpus Striatum; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drug I | 2016 |
DREADD Modulation of Transplanted DA Neurons Reveals a Novel Parkinsonian Dyskinesia Mechanism Mediated by the Serotonin 5-HT6 Receptor.
Topics: Animals; Clozapine; Cyclic AMP; Diterpenes; Diterpenes, Clerodane; Dopamine; Dopaminergic Neurons; D | 2016 |
Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Dioxygenases; Disease Models, | 2016 |
Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.
Topics: Aging; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Ind | 2016 |
l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Down-Regulation; Dyskinesia, | 2016 |
Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action.
Topics: Animals; Anti-Dyskinesia Agents; Arachidonic Acids; Brain; Cannabidiol; Capsaicin; Cyclooxygenase 2; | 2016 |
Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agents; Dopamine Antagonists; Dose-R | 2016 |
L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induce | 2016 |
The impact of l-dopa on attentional impairments in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Attention; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2016 |
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Cytokines; Disease Models, Animal; Drug Delivery Sys | 2016 |
Dysregulation of BET proteins in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Azepines; Chromatin Immunoprecipitation; Corpus Striatum; Disease Mod | 2017 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease M | 2008 |
Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
Topics: Animals; Anti-Inflammatory Agents; Corpus Striatum; Corticosterone; Disease Models, Animal; Dose-Res | 2008 |
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
Topics: Animals; Animals, Newborn; Brain; Cerebral Cortex; Cyclic AMP; Cyclic GMP; Dopamine; Dopamine Agents | 2008 |
Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements.
Topics: Adrenergic Agents; Animals; Dopamine Agonists; Dyskinesia, Drug-Induced; Dyskinesias; Male; Oxidopam | 2008 |
Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Creatine; Dietary Supplements; Disease Models, | 2009 |
Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Benzazepines; Biogenic Monoamine | 2008 |
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cerebrum; Dendritic Spines; Disease Mod | 2009 |
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, D | 2008 |
Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Levodopa | 2009 |
Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model.
Topics: Animals; Antiparkinson Agents; Circadian Rhythm; Disease Models, Animal; Dyskinesia, Drug-Induced; F | 2009 |
Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; | 2009 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix | 2009 |
Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Analysis of Variance; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents | 2009 |
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Benserazide; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dys | 2009 |
L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
Topics: Animals; Brain; Brain Chemistry; Corpus Striatum; Dopamine Agents; Drug Interactions; Dyskinesia, Dr | 2009 |
Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; En | 2009 |
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Sti | 2009 |
Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.
Topics: Amphetamine; Analysis of Variance; Animals; Benserazide; Brain; Dopamine Agents; Dyskinesia, Drug-In | 2011 |
Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Topics: Acetylation; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; | 2009 |
Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-I | 2009 |
Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Benzazepines; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Mal | 2009 |
Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dose-Respo | 2009 |
Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Dopamine Agents; Dynorphins; Dyskinesia, Drug-Induced; | 2009 |
Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopam | 2009 |
Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances.
Topics: Animals; Benzylamines; Cognition Disorders; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Mal | 2009 |
Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not neuroprotection.
Topics: Administration, Oral; Adrenergic Agents; Animals; Antioxidants; Catechin; Cell Count; Dopamine; Dysk | 2009 |
The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzopyrans; Disability Evaluation; Dopamine Antagonists; Dose-Respon | 2010 |
The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; | 2010 |
The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Antiparkinson Agents | 2010 |
Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Microdialysis; | 2010 |
L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodo | 2010 |
MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dyskinesia, Drug-Induced | 2010 |
The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Disease Models, Animal; Dyskinesia, Drug-Induced; Fem | 2010 |
Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo.
Topics: Animals; Brain Tissue Transplantation; Cell Survival; Cells, Cultured; Dopamine; Dyskinesia, Drug-In | 2010 |
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-I | 2010 |
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agoni | 2010 |
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Imidazoles; | 2010 |
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Adamantane; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Calcium; Callithrix | 2010 |
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparasitic Agents; Corpus Striatum; Cyclin-Dependent Kinase 5; Disease Models, Animal; D | 2010 |
A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Disease Models, Anima | 2010 |
Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.
Topics: Action Potentials; Animals; Antiparkinson Agents; Behavior, Animal; Cholera Toxin; Corpus Striatum; | 2010 |
Proteasome inhibition in medaka brain induces the features of Parkinson's disease.
Topics: Acetylcysteine; Animals; Behavior, Animal; Blotting, Western; Brain Chemistry; Cysteine Proteinase I | 2010 |
Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; L | 2011 |
L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.
Topics: Adenylyl Cyclases; Animals; Dyskinesia, Drug-Induced; Enzyme Inhibitors; gamma-Aminobutyric Acid; Le | 2011 |
Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Disease Models, Animal; | 2011 |
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Brain-Derived Neurotrophic Factor; Corp | 2010 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Bens | 2011 |
BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Area Under Curve; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; | 2011 |
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Allosteric Regulation; Analysis of Variance; Animals; Brain; Calcium; Cognition D | 2011 |
Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
Topics: Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; | 2011 |
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
Topics: Animals; Corpus Striatum; Cyclic GMP; Dyskinesia, Drug-Induced; Levodopa; Long-Term Synaptic Depress | 2011 |
Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats.
Topics: Analysis of Variance; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Indu | 2011 |
Modulation of excessive neuronal activity by fibroblasts: potential use in treatment of Parkinson's disease.
Topics: Animals; Dyskinesia, Drug-Induced; Fibroblasts; Motor Activity; Neurons; Oxidopamine; Parkinson Dise | 2010 |
Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat.
Topics: Animals; Conditioning, Psychological; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dysk | 2011 |
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Azetidines; Benzazepines; Corpus Striatum; Disease Models, Animal; Do | 2011 |
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dose-R | 2011 |
Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal | 2011 |
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Benzazepines; Ch | 2011 |
Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
Topics: Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Benzoxazines; Corpus Striatum; Disease M | 2011 |
Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopa Decarboxylase | 2011 |
Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Disease Models, An | 2012 |
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.
Topics: Animals; Antiparkinson Agents; Aporphines; Binding, Competitive; CHO Cells; Corpus Striatum; Criceti | 2011 |
Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cell Count; Combined Modality Therapy; Dopamine; Dy | 2011 |
Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats.
Topics: Animals; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug | 2011 |
Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.
Topics: Animals; Antiparkinson Agents; Autoradiography; Bridged Bicyclo Compounds, Heterocyclic; Corpus Stri | 2011 |
Posterior hypothalamic nucleus deep brain stimulation restores locomotion in rats with haloperidol-induced akinesia but not skilled forelimb use in pellet reaching and lever pressing.
Topics: Adrenergic Agents; Animals; Anti-Dyskinesia Agents; Conditioning, Operant; Deep Brain Stimulation; D | 2011 |
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Calcium-Calmodulin-Dependent | 2012 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, | 2011 |
Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
Topics: Action Potentials; Animals; Antiparkinson Agents; Corpus Striatum; D-Aspartate Oxidase; D-Aspartic A | 2011 |
Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation.
Topics: Amphetamines; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopami | 2011 |
Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induce | 2012 |
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benserazide; Disease Models, Animal; D | 2011 |
Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Neurons; Animals; Behavior, An | 2012 |
Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Calpain; Corpus Striatum; Cyclin-Dependent Kinase 5 | 2012 |
Retigabine, a K(V)7 (KCNQ) potassium channel opener, attenuates L-DOPA-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Amantadine; Aminopyridines; Animals; Anticonvulsants; Antiparkinson Agents; Behavior, Animal; Carbam | 2012 |
Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Autorad | 2012 |
Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia.
Topics: Adaptor Proteins, Signal Transducing; Adrenergic Agents; Animals; Antiparkinson Agents; Cell Line, T | 2011 |
The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.
Topics: Animals; Behavior, Animal; Benzoxazines; Cannabinoids; Cyclic AMP-Dependent Protein Kinases; Dopamin | 2012 |
Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
Topics: Animals; Anti-Dyskinesia Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino | 2012 |
Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study.
Topics: Amphetamine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamin | 2012 |
Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Topics: Allosteric Regulation; Aminobutyrates; Anilides; Animals; Catalepsy; Cyclohexanecarboxylic Acids; Di | 2013 |
Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Brain; Corpus Striatum; Drug Inter | 2012 |
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinso | 2012 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; An | 2013 |
The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats.
Topics: Animals; Dyskinesia, Drug-Induced; Electrophysiological Phenomena; Levodopa; Neostriatum; Neurons; O | 2012 |
Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.
Topics: Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-In | 2013 |
Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Autoradiography; Behavior, Animal; Dyskinesia | 2012 |
Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations.
Topics: Algorithms; Animals; Antiparkinson Agents; Cerebral Cortex; Dyskinesia, Drug-Induced; Electrodes, Im | 2012 |
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease | 2012 |
Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.
Topics: Animals; Benzothiazoles; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Dyski | 2012 |
Short- and long-term unilateral 6-hydroxydopamine lesions in rats show different changes in characteristics of spontaneous firing of substantia nigra pars reticulata neurons.
Topics: Action Potentials; Adrenergic Agents; Animals; Brain Injuries; Dyskinesia, Drug-Induced; Forelimb; F | 2013 |
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Blotting, Western; Dyskinesia, Drug-Induced; Immun | 2013 |
Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adamantane; Alternative Splicing; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease M | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, | 2013 |
Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease.
Topics: Amino Acids; Animals; Antiparkinson Agents; Behavior, Animal; Bridged Bicyclo Compounds, Heterocycli | 2002 |
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Topics: Afferent Pathways; Animals; Bacterial Proteins; Behavior, Animal; Biomarkers; Brain Mapping; Caudate | 2002 |
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; En | 2002 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine A | 2002 |
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Diben | 2002 |
AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport P | 2002 |
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dyski | 2003 |
Intrastriatal serotonin 5-HT2 receptors mediate dopamine D1-induced hyperlocomotion in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Benzazepines; Denervation; Dopamine; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug | 2003 |
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benzazepines; Benzoxazines; Brain Ch | 2003 |
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkin | 2003 |
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Dis | 2003 |
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine A | 2004 |
Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.
Topics: Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine A | 2004 |
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mazindol | 2004 |
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Topics: Animals; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catecho | 2005 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal | 2005 |
Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Corpu | 2005 |
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Blotting, Western; Corpus Striatum; Disease Models, | 2006 |
Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic | 2005 |
Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dysk | 2005 |
Modulation of torsinA expression in the globus pallidus internus is associated with levodopa-induced dyskinesia in hemiparkinsonian rats.
Topics: Animals; Cell Count; Disease Models, Animal; Dopamine Agents; Down-Regulation; Dyskinesia, Drug-Indu | 2006 |
Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; L | 2006 |
The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamin | 2006 |
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskin | 2006 |
Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enviro | 2006 |
Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; L | 2006 |
MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dose-Respons | 2006 |
Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.
Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Binding, Competitive; Bi | 2006 |
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
Topics: Animals; Antibodies, Monoclonal; Antigens; Basal Ganglia; Biomarkers; Blood-Brain Barrier; Bromodeox | 2006 |
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 2007 |
The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Combined Modality Therapy; Corpus Striatum; | 2007 |
Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, In | 2006 |
Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons.
Topics: Adrenergic Uptake Inhibitors; Animals; Cell Death; Desipramine; Disease Models, Animal; Dopamine; Do | 2007 |
Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain; Brain Mapping; Disease Models, Animal; Dopam | 2007 |
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pres | 2007 |
Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease M | 2007 |
Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.
Topics: Animals; Brain; Cyclic AMP; Disease Models, Animal; Dopamine Agonists; Dopamine and cAMP-Regulated P | 2007 |
Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa.
Topics: Amino Acid Sequence; Animals; Basal Ganglia; Brain Chemistry; Dopamine; Dopamine and cAMP-Regulated | 2007 |
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Basal Ganglia; Benzamides; Benzox | 2007 |
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Ben | 2008 |
Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Mo | 2008 |
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Resp | 2008 |
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nerv | 2008 |
Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Dr | 2008 |
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.
Topics: Adrenergic Agents; Amphetamine; Animals; Anti-Anxiety Agents; Behavior, Animal; Dextromethorphan; Di | 2008 |
Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxi | 2007 |
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Corpus St | 2008 |
Dopamine inhibitory and excitatory systems in tardive dyskinesias.
Topics: Animals; Apomorphine; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced | 1983 |
Persistent oral dyskinesias in haloperidol-withdrawn neonatal 6-hydroxydopamine-lesioned rats.
Topics: Animals; Animals, Newborn; Dyskinesia, Drug-Induced; Haloperidol; Mouth; Oxidopamine; Rats; Rats, Sp | 1994 |
Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia.
Topics: Adrenergic Agents; Amphetamine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Dru | 1996 |
Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: absence of an association with the Bmax for [3H]raclopride binding to neostriatal homogenates.
Topics: Animals; Antipsychotic Agents; Biogenic Monoamines; Corpus Striatum; Dopamine; Dopamine Antagonists; | 1997 |
Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Animals, | 1998 |
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Behavior, An | 1998 |
L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.
Topics: Animals; Autoradiography; Behavior, Animal; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephalins; | 1998 |
Compartmental changes in expression of c-Fos and FosB proteins in intact and dopamine-depleted striatum after chronic apomorphine treatment.
Topics: Animals; Apomorphine; Behavior, Animal; Calbindins; Corpus Striatum; Denervation; Dopamine; Dopamine | 1999 |
Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Brain Mapping; Corpus Striatum; Dementia; Dopa | 1999 |
A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biological Availability; Body Weight; Circadi | 1999 |
Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Cocaine; Denervation; | 2000 |
Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Gene Expression Regulation; Genes, fos | 2000 |
Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Basal Ganglia; Behavior, Animal; Binding Sites; Cerebral Cortex; Diprenorphine; Disease Mod | 2001 |
Entopeduncular lesions facilitate and thalamic lesions depress spontaneous and drug-evoked motor behavior in the hemiparkinsonian rat.
Topics: Amphetamine; Animals; Apomorphine; Denervation; Disease Models, Animal; Dopamine Agonists; Dyskinesi | 2001 |
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocil | 2002 |
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Dyskinesia, | 2002 |
Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats.
Topics: Animals; Animals, Newborn; Behavior, Animal; Drug Resistance; Dyskinesia, Drug-Induced; Female; Oxid | 1992 |
Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue.
Topics: Animals; Carbidopa; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Res | 1991 |
Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Aci | 1991 |
Relationships between indices of behavioral asymmetries and neurochemical changes following mesencephalic 6-hydroxydopamine injections.
Topics: Analysis of Variance; Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Functional Later | 1991 |
Effects of 5,7-dihydroxytryptamine and 6-hydroxydopamine on head-twitch response induced by serotonin, p-chloroamphetamine, and tryptamine in mice.
Topics: 5,7-Dihydroxytryptamine; Amphetamines; Animals; Behavior, Animal; Brain Chemistry; Dihydroxytryptami | 1988 |